TriMas Corporation (NASDAQ:TRS - Get Free Report) reached a new 52-week high on Thursday . The company traded as high as $39.80 and last traded at $39.89, with a volume of 78037 shares traded. The stock had previously closed at $39.12.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on TRS shares. BWS Financial reaffirmed a "buy" rating and issued a $45.00 price target (up from $40.00) on shares of TriMas in a research note on Wednesday, July 30th. Zacks Research raised shares of TriMas from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 29th. KeyCorp set a $45.00 price target on shares of TriMas and gave the stock an "overweight" rating in a research note on Tuesday, August 12th. Finally, Wall Street Zen raised shares of TriMas from a "hold" rating to a "buy" rating in a research report on Sunday, June 1st. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $45.00.
Get Our Latest Research Report on TriMas
TriMas Trading Down 0.5%
The stock has a market cap of $1.62 billion, a P/E ratio of 43.67 and a beta of 0.65. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.59 and a quick ratio of 1.44. The business's 50 day simple moving average is $36.23 and its 200 day simple moving average is $28.90.
TriMas (NASDAQ:TRS - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The industrial products company reported $0.61 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.11. The firm had revenue of $274.76 million during the quarter, compared to analysts' expectations of $251.18 million. TriMas had a net margin of 3.83% and a return on equity of 11.49%. The company's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.43 earnings per share. TriMas has set its FY 2025 guidance at 1.950-2.100 EPS. On average, analysts expect that TriMas Corporation will post 1.69 earnings per share for the current fiscal year.
TriMas Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Tuesday, August 12th. Stockholders of record on Tuesday, August 5th were paid a $0.04 dividend. The ex-dividend date was Tuesday, August 5th. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.4%. TriMas's payout ratio is 17.58%.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Irenic Capital Management LP acquired a new stake in shares of TriMas in the first quarter valued at approximately $19,997,000. Alta Fox Capital Management LLC acquired a new stake in shares of TriMas in the first quarter valued at approximately $17,385,000. Simcoe Capital Management LLC acquired a new stake in shares of TriMas in the first quarter valued at approximately $6,451,000. Ophir Asset Management Pty Ltd acquired a new stake in shares of TriMas in the second quarter valued at approximately $7,261,000. Finally, Nuveen LLC acquired a new stake in shares of TriMas in the first quarter valued at approximately $5,932,000. Institutional investors own 99.42% of the company's stock.
About TriMas
(
Get Free Report)
TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace, and industrial markets worldwide. The company operates through Packaging, Aerospace, and Specialty Products segments. The Packaging segment offers dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, and flexible spouts; polymeric jar products; integrated dispensers; bag-in-box products; and consumable vascular delivery and diagnostic test components under the Rieke, Taplast, Affaba & Ferrari, Intertech, Omega, and Rapak brands.
Featured Articles
Before you consider TriMas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriMas wasn't on the list.
While TriMas currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.